Karyopharma Reports FDA AdCom Panel Reviewing Selinexor For Treatment Of Patients With Triple Class Refractory Multiple Myeloma Voted 8-5 Recommending FDA Wait For Results From Phase 3 BOSTON Study Before Making Final Decision Related To Approval
Benzinga Newsdesk